2VJ Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
Ascletis Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.18 |
| 52 Week High | HK$0.21 |
| 52 Week Low | HK$0.084 |
| Beta | 0.57 |
| 11 Month Change | 18.71% |
| 3 Month Change | 113.95% |
| 1 Year Change | -2.13% |
| 33 Year Change | -43.03% |
| 5 Year Change | -66.85% |
| Change since IPO | -84.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.5% | -0.7% | -0.02% |
| 1Y | -2.1% | -17.2% | 8.2% |
Return vs Industry: 2VJ exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 2VJ underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 2VJ volatility | |
|---|---|
| 2VJ Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2VJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2VJ's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 219 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
| 2VJ fundamental statistics | |
|---|---|
| Market cap | €213.41m |
| Earnings (TTM) | -€34.26m |
| Revenue (TTM) | €1.34m |
159.6x
P/S Ratio-6.2x
P/E RatioIs 2VJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VJ income statement (TTM) | |
|---|---|
| Revenue | CN¥10.09m |
| Cost of Revenue | CN¥22.72m |
| Gross Profit | -CN¥12.63m |
| Other Expenses | CN¥245.84m |
| Earnings | -CN¥258.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -125.17% |
| Net Profit Margin | -2,561.68% |
| Debt/Equity Ratio | 0% |
How did 2VJ perform over the long term?
See historical performance and comparison